Do people with amazing memory in their 80s just have lucky genes?
No. In 231 older adults, neither APOE genotype nor any of three Alzheimer’s polygenic risk scores predicted who had exceptional memory after age 80. SuperAgers and their cognitively average peers carried essentially the same inherited Alzheimer’s risk.
That result runs against a reasonable guess. If Alzheimer’s disease sits at one end of a line, you might expect exceptional memory to sit at the other end, driven by simply not inheriting the risk genes. This study says the line does not work that way. Whatever protects a SuperAger’s memory seems to be something other than the absence of common Alzheimer’s risk variants.
Who counts as a SuperAger
A SuperAger is not just a healthy older person. The label comes from a strict, pre-set performance rule. Participants had to be at least 80 years old and score at or above the average for adults aged 56 to 64 on a delayed word recall test called the Rey Auditory Verbal Learning Test. In practice that means recalling nine or more words after a delay, a standard score of 10 or higher on Mayo’s Older Americans Normative Studies norms. They also had to perform within or above normal range for their own age on naming, category fluency, and a timed attention and switching task.
The comparison group met the same age and health requirements but scored in the typical range for their age. Everyone was enrolled prospectively, meaning the cognitive rules were written before anyone was tested, not chosen after the fact to fit a result.
What the data show
The researchers studied 231 participants, 142 SuperAgers and 89 cognitively average controls, all enrolled through the multisite SuperAging Research Initiative. The consortium recruits across five North American regions: Ann Arbor and Detroit, Atlanta, Chicago, London in Ontario, and Madison.
APOE allele and genotype patterns, including the risk-raising ε4 and the usually protective ε2, did not differ between the two groups. Neither did any of the three polygenic risk scores, built from large modern genome-wide studies and labeled by their source datasets as Lambert, Wightman, and Bellenguez. A polygenic risk score adds up thousands of small genetic effects into a single number for inherited liability. All three came out the same in SuperAgers and controls once the models adjusted for age, sex, and education.
The team also checked whether ancestry hid an effect. Genetic ancestry structure was comparable across the groups, and the findings did not change after accounting for global non-European or African ancestry or for ancestry principal components.
Dr. Kumar’s Take
I find negative results like this more interesting than most positive ones, because they close off an easy explanation. It would be tidy if SuperAgers were simply people who drew a good genetic hand on Alzheimer’s. They are not, at least not for the common variants medicine can currently measure.
What that leaves is more interesting to me clinically. It points toward active protection: something in these brains, or in how these people have lived, that holds memory circuits together while peers of the same age drift. Rare genetic variants that standard scores do not capture are one candidate. Decades of experience, engagement, and relationships are another. I would not oversell either yet. This is one cohort, and the sample of 231 is respectable for deep phenotyping but modest for genetics, so a small real effect could hide inside it.
How strong is the evidence?
The strengths here are real. The SuperAger definition was set in advance and applied uniformly across sites, which avoids the circular reasoning that plagues a lot of cognitive aging research. Multisite recruitment widens the geographic and demographic net beyond the original Chicago cohort, and the ancestry-aware analysis is a step past older studies that mostly enrolled people of European ancestry.
The limits matter too. This is a cross-sectional comparison, not a study that followed people forward to see who stayed sharp. Everyone had to be healthy enough and willing enough to enroll in an intensive research program, which selects for a particular kind of participant. And earlier large multi-cohort work has reported lower ε4 and higher ε2 rates among people with superior cognition, so the literature is not unanimous. This study is the more tightly defined phenotype; that does not automatically make every other finding wrong.
Practical Takeaways
- A family history of Alzheimer’s or an ε4 result does not rule out excellent memory in your 80s, and a clean genetic profile does not guarantee it, so treat genetic risk as one input rather than a verdict.
- If you have had APOE testing through a consumer service, discuss the result with your physician before drawing conclusions about your cognitive future, because the number tells you far less about exceptional aging than most people assume.
- Keep investing in the modifiable side of brain health, including sleep, blood pressure, hearing, exercise, and social engagement, since the protective mechanisms this study points toward are more likely to live there than in your genome.
Related Studies and Research
- The high-dose flu shot may lower Alzheimer’s risk in older adults
- Eating eggs regularly linked to lower Alzheimer’s risk in older adults
- The shingles vaccine may cut dementia risk by a third in older adults
- Long daytime naps linked to higher death risk in older adults
FAQs
Should I get APOE testing to find out how my memory will age?
For most people, no, and this study is part of the reason. APOE status shifts the odds of developing Alzheimer’s disease, but it did nothing to separate people with exceptional memory from people with ordinary memory at the same advanced age. A result you cannot act on can still cause real anxiety, and there is currently no treatment that changes based on your APOE genotype alone. If you do want testing, do it through a clinician or genetic counselor who can put the number in context rather than through a mail-in kit that hands you a percentage with no interpretation.
What is a polygenic risk score, and why did three of them all come up empty?
Alzheimer’s risk is spread across thousands of genetic variants that each nudge risk slightly. A polygenic risk score compresses all of those nudges into one number, and different research teams build these scores from different genome-wide datasets, which is why the study tested three separate versions. Using all three is a way of asking whether the null result was an artifact of one particular scoring method. None of them predicted SuperAger status, which makes the finding harder to dismiss as a quirk of how one score was built.
Why does it matter that the results held across genetic ancestries?
Most Alzheimer’s genetics research has been done in people of European ancestry, and risk scores built on that data often perform poorly in everyone else. If this study had only found a null result in one ancestry group, the obvious objection would be that the scores were simply mismatched to the population. The researchers confirmed the ancestry structure was comparable between SuperAgers and controls, then re-ran the analysis accounting for non-European and African ancestry and for principal components. The answer stayed the same, which suggests the finding is about the SuperAging phenotype itself and not about which population was studied.
Bottom Line
Exceptional memory after 80 is not simply the mirror image of Alzheimer’s disease. Across 231 carefully characterized older adults at five North American sites, SuperAgers carried the same common-variant Alzheimer’s risk as their cognitively average peers, whether measured by APOE or by three modern polygenic risk scores, and the pattern held across genetic ancestries. The most useful reading is that something is actively protecting these brains rather than something being absent from them, and finding out what that is will take research into rare genetic variation and into how these people have actually lived.
